CO2018000303A2 - Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo - Google Patents

Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo

Info

Publication number
CO2018000303A2
CO2018000303A2 CONC2018/0000303A CO2018000303A CO2018000303A2 CO 2018000303 A2 CO2018000303 A2 CO 2018000303A2 CO 2018000303 A CO2018000303 A CO 2018000303A CO 2018000303 A2 CO2018000303 A2 CO 2018000303A2
Authority
CO
Colombia
Prior art keywords
composition
long acting
glucagon derivative
acting conjugate
peptide
Prior art date
Application number
CONC2018/0000303A
Other languages
English (en)
Inventor
Jung Kuk Kim
Sung Youb Jung
Young Jin Park
In Young Choi
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of CO2018000303A2 publication Critical patent/CO2018000303A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende un péptido que comprende la secuencia de aminoácidos de Fórmula 1 y al menos un compuesto o material que es un péptido insulinotrópico según se define en la reivindicación 1. La invención se refiere también a un péptido aislado que comprende la secuencia de aminoácidos de Fórmula 2 y a un conjugado en el que dicho péptido está unido a un material biocompatible.
CONC2018/0000303A 2015-06-30 2018-01-15 Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo CO2018000303A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150093265 2015-06-30
PCT/KR2016/006984 WO2017003191A1 (en) 2015-06-30 2016-06-29 Glucagon derivative and a composition comprising a long acting conjugate of the same

Publications (1)

Publication Number Publication Date
CO2018000303A2 true CO2018000303A2 (es) 2018-07-10

Family

ID=57608802

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0000303A CO2018000303A2 (es) 2015-06-30 2018-01-15 Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo

Country Status (31)

Country Link
US (3) US10696725B2 (es)
EP (2) EP4324519A2 (es)
JP (3) JP6882210B2 (es)
KR (2) KR102005456B1 (es)
CN (1) CN108025041A (es)
AR (1) AR105485A1 (es)
AU (2) AU2016287209B2 (es)
BR (1) BR112017028517A2 (es)
CA (1) CA2991107A1 (es)
CL (5) CL2017003402A1 (es)
CO (1) CO2018000303A2 (es)
CR (1) CR20180034A (es)
DK (1) DK3322437T3 (es)
DO (1) DOP2017000318A (es)
EA (1) EA201890058A1 (es)
EC (1) ECSP18003879A (es)
FI (1) FI3322437T3 (es)
HK (1) HK1248129A1 (es)
IL (2) IL256619B (es)
MA (2) MA49545B1 (es)
MX (1) MX2017016845A (es)
NZ (1) NZ739250A (es)
PE (2) PE20180449A1 (es)
PH (1) PH12017502393A1 (es)
PL (1) PL3322437T3 (es)
PT (1) PT3322437T (es)
TN (1) TN2017000555A1 (es)
TW (1) TWI713541B (es)
UA (1) UA127445C2 (es)
UY (1) UY36759A (es)
WO (1) WO2017003191A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
MA40709B1 (fr) * 2014-12-30 2019-07-31 Hanmi Pharmaceutical Co Ltd Dérivé du glucagon à stabilité améliorée
KR102005456B1 (ko) 2015-06-30 2019-07-30 한미약품 주식회사 신규 글루카곤 유도체 및 이의 지속형 결합체를 포함하는 조성물
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
PE20181494A1 (es) 2015-12-31 2018-09-18 Hanmi Pharm Ind Co Ltd Conjugado persistente de triple activador que activa el receptor de glucagon, glp-1 u gip
CA3029518A1 (en) * 2016-06-29 2018-01-04 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof
US20200230250A1 (en) * 2017-02-03 2020-07-23 Hanmi Pharm. Co., Ltd. Long-acting conjugate of a physiologically active material and use thereof
US11925691B2 (en) 2017-02-07 2024-03-12 Hanmi Pharm. Co., Ltd. Non-peptidic polymeric linker compound, conjugate comprising same linker compound, and methods for preparing same linker compound and conjugate
CN111406073A (zh) * 2017-09-29 2020-07-10 韩美药品株式会社 具有提高功效的持久性蛋白质缀合物
KR20200135618A (ko) * 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
KR101990075B1 (ko) * 2018-07-19 2019-06-18 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물
WO2020017919A1 (ko) * 2018-07-19 2020-01-23 한미정밀화학주식회사 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법
CN112912095A (zh) 2018-07-19 2021-06-04 D&D制药技术股份有限公司 包括多肽的药物组合物
US20210338779A1 (en) * 2018-10-04 2021-11-04 Hanmi Pharm. Co., Ltd Therapeutic use of glucagon and combination including the same
CN109239346B (zh) * 2018-10-31 2019-10-11 中国药科大学 一组代谢标志物在代谢综合征早期诊断方面的应用
US20220064248A1 (en) 2018-12-21 2022-03-03 HANMl PHARM. CO., LTD Pharmaceutical composition including insulin and glucagon
CA3122427A1 (en) * 2019-06-28 2020-12-30 Hanmi Pharm Co., Ltd. Therapeutic use of trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof for liver disease
KR20210040818A (ko) * 2019-10-04 2021-04-14 한미약품 주식회사 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도
CN112898406B (zh) * 2019-10-12 2023-11-10 深圳纳福生物医药有限公司 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
IL295744A (en) * 2020-02-21 2022-10-01 Spitfire Pharma Llc glp-1r and gcgr agonists, formulations and methods of use
US20230192800A1 (en) 2020-05-22 2023-06-22 Hanmi Pharm. Co., Ltd. Liquid formulation of long-acting conjugate of glucagon derivative
CN116096397A (zh) 2020-07-15 2023-05-09 韩美药品株式会社 胰高血糖素衍生物或其缀合物对于肝脏疾病的治疗用途
EP4197550A1 (en) * 2020-08-14 2023-06-21 Hanmi Pharm. Co., Ltd. Hypotensive pharmaceutical composition comprising triple activator having activity for all of glucagon, glp-1, and gip receptors
CN117157094A (zh) 2021-04-09 2023-12-01 韩美药品株式会社 包括胰高血糖素衍生物的用于预防或治疗慢性肾病的药物组合物
KR20230095666A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 물질 및 이의 용도

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
GB9423277D0 (en) 1994-11-18 1995-01-11 Univ Nottingham Pulsed laser deposition of coatings
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
EP2275117B1 (en) 2001-07-31 2016-10-26 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, exendin-4, peptide analogs and uses thereof
UA92451C2 (en) 2003-03-19 2010-11-10 Эли Лилли Энд Компани Polyethelene glycol link glp-1 compounds
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
KR100775343B1 (ko) * 2003-11-13 2007-11-08 한미약품 주식회사 면역글로불린 Ｆｃ 영역을 캐리어로 포함하는 약제학적조성물
EP2573111A1 (en) 2006-04-20 2013-03-27 Amgen Inc. GLP-1 compounds
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
ES2628063T3 (es) 2007-01-05 2017-08-01 Indiana University Research And Technology Corporation Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos
KR20150116465A (ko) 2007-02-15 2015-10-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
JP5385266B2 (ja) 2007-06-15 2014-01-08 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
CN102015761A (zh) 2007-06-19 2011-04-13 大塚化学株式会社 附加糖链的glp-1肽
JP5476304B2 (ja) 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー／エス グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
JP2011511778A (ja) 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
EA019203B9 (ru) 2008-06-17 2014-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты глюкагонового рецептора/glp-1-рецептора
KR20110039230A (ko) * 2008-06-17 2011-04-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체
EP2300035B1 (en) 2008-06-17 2015-08-12 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
EP2443146B1 (en) * 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
EP2454282B1 (en) 2009-07-13 2015-03-04 Zealand Pharma A/S Acylated glucagon analogues
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CA2786934A1 (en) 2010-01-20 2011-07-28 Zealand Pharma A/S Treatment of cardiac conditions
US20130143798A1 (en) 2010-03-26 2013-06-06 Novo Nordisk A/S Novel glucagon analogues
KR20130111923A (ko) 2010-05-13 2013-10-11 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CN103458920B (zh) 2010-12-22 2016-07-06 印第安那大学科技研究公司 表现出gip受体活性的胰高血糖素类似物
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
KR102255479B1 (ko) 2011-05-18 2021-05-24 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약
AU2012267398B2 (en) 2011-06-10 2016-10-13 Hanmi Science Co., Ltd. Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
RU2733544C2 (ru) 2011-06-17 2020-10-05 Ханми Сайенс Ко., Лтд. Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение
US9944687B2 (en) 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
BR112014007124A2 (pt) 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
WO2013120022A2 (en) 2012-02-08 2013-08-15 Seneb Biosciences, Inc. Treatment of hypoglycemia
US9745359B2 (en) 2012-05-18 2017-08-29 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
EA029025B1 (ru) 2012-06-21 2018-01-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, проявляющие активность на рецепторе gip
JP6311708B2 (ja) 2012-06-21 2018-04-18 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Ｇｉｐ受容体活性を示すグルカゴンアナローグ
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
EA039082B1 (ru) * 2012-11-06 2021-12-01 Ханми Фарм. Ко., Лтд. Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина
CA2891929C (en) 2012-11-20 2022-07-19 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
KR102365582B1 (ko) 2012-11-20 2022-02-18 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 약제
EP2934569A1 (en) 2012-12-21 2015-10-28 Sanofi Exendin-4 derivatives
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
CN106456589B (zh) 2013-12-18 2020-07-07 斯克利普斯研究所 修饰的治疗剂、订合的肽脂质缀合物及其组合物
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
WO2016049190A1 (en) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Incretin-insulin conjugates
WO2016077806A1 (en) * 2014-11-13 2016-05-19 AskGene Pharma, Inc. Fusion proteins with dual receptor agonist activities
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
MA40709B1 (fr) 2014-12-30 2019-07-31 Hanmi Pharmaceutical Co Ltd Dérivé du glucagon à stabilité améliorée
KR102005456B1 (ko) * 2015-06-30 2019-07-30 한미약품 주식회사 신규 글루카곤 유도체 및 이의 지속형 결합체를 포함하는 조성물
US20170004368A1 (en) 2015-07-05 2017-01-05 Neteera Technologies Ltd. System and method for biometric detection based on sweat ducts
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
JP6989503B2 (ja) 2015-12-02 2022-01-05 ハンミ ファーマシューティカル カンパニー リミテッド 脂肪酸誘導体を用いたタンパク質結合体及びその製造方法
PE20181494A1 (es) 2015-12-31 2018-09-18 Hanmi Pharm Ind Co Ltd Conjugado persistente de triple activador que activa el receptor de glucagon, glp-1 u gip

Also Published As

Publication number Publication date
UA127445C2 (uk) 2023-08-30
EP3322437A1 (en) 2018-05-23
CL2023000198A1 (es) 2023-06-30
TN2017000555A1 (en) 2019-04-12
DOP2017000318A (es) 2018-04-30
HK1248129A1 (zh) 2018-10-12
IL256619A (en) 2018-04-30
DK3322437T3 (da) 2024-03-25
AR105485A1 (es) 2017-10-11
EP4324519A2 (en) 2024-02-21
PE20180449A1 (es) 2018-03-05
JP2021102618A (ja) 2021-07-15
IL291291B2 (en) 2023-06-01
JP6882210B2 (ja) 2021-06-02
CL2023001909A1 (es) 2023-11-17
US20180186853A1 (en) 2018-07-05
PT3322437T (pt) 2024-03-20
NZ739250A (en) 2024-02-23
BR112017028517A2 (pt) 2018-08-28
US20220127325A1 (en) 2022-04-28
EP3322437A4 (en) 2019-10-09
MA49545A1 (fr) 2021-09-30
MA49545B1 (fr) 2022-03-31
US11261227B2 (en) 2022-03-01
ECSP18003879A (es) 2018-03-31
EA201890058A1 (ru) 2018-07-31
PL3322437T3 (pl) 2024-05-20
JP2023062043A (ja) 2023-05-02
UY36759A (es) 2017-01-31
AU2016287209A1 (en) 2018-02-15
CA2991107A1 (en) 2017-01-05
US20200223897A1 (en) 2020-07-16
CR20180034A (es) 2018-04-16
CL2017003402A1 (es) 2018-04-20
CL2023001911A1 (es) 2023-11-17
IL291291A (en) 2022-05-01
PE20240215A1 (es) 2024-02-16
WO2017003191A1 (en) 2017-01-05
CN108025041A (zh) 2018-05-11
KR102395855B1 (ko) 2022-05-10
KR20170003466A (ko) 2017-01-09
TWI713541B (zh) 2020-12-21
MX2017016845A (es) 2018-08-01
PH12017502393A1 (en) 2018-06-25
TW201713681A (zh) 2017-04-16
IL256619B (en) 2022-04-01
EP3322437B1 (en) 2024-01-17
MA41887A1 (fr) 2018-12-31
FI3322437T3 (fi) 2024-02-20
JP2018526333A (ja) 2018-09-13
KR20190092343A (ko) 2019-08-07
MA41887B1 (fr) 2020-05-29
US11667688B2 (en) 2023-06-06
AU2016287209B2 (en) 2023-03-02
KR102005456B1 (ko) 2019-07-30
AU2023201118A1 (en) 2023-04-20
US10696725B2 (en) 2020-06-30
CL2023001910A1 (es) 2023-11-17

Similar Documents

Publication Publication Date Title
CO2018000303A2 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CY1123595T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5
CO2018000078A2 (es) Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
MX2019009861A (es) Composiciones farmaceuticas de un derivado de acido biliar y microbioma y usos de las mismas.
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
CR20190063A (es) 3-metil pirazinas 2,5-disustituídas y 3-metil pirazinas 2,5,6-trisustituídas como inhibidores alostéricos de shp2
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
SV2018005643A (es) Composiciones de insulina de rapida accion
IL286592A (en) Amino acid compounds for the treatment of liver disease
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
BR112017012381A2 (pt) imunoterapia para doença angiogênica
CY1124115T1 (el) Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
MX2018015410A (es) Esteres de oxaborol y sus usos.
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
DOP2017000240A (es) Derivados de aminohidrotiazina fusionados con tetrahidrofurano los cuales son útiles en el tratamiento de la enfermedad de alzheimer
CL2017001159A1 (es) Composiciones farmacéuticas de larga duración para la hepatitis c
MX362058B (es) Péptido pntx(19) sintético, composición farmacéutica y uso.
EA201890477A1 (ru) Инкапсулированная композиция финголимода
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
BR112017024126A2 (pt) composições farmacêuticas e uso das mesmas
BR112018003714A8 (pt) Composições de ácido de peso aumentado que compreendem aminoácidos